EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer

Yuichi Ozawa, Yasuhiro Koh, Ryota Shibaki, Yuhei Harutani, Hiroaki Akamatsu, Atsushi Hayata, Takeya Sugimoto, Yuka Kitamura, Junya Fukuoka, Masanori Nakanishi, Nobuyuki Yamamoto

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03861-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Yuichi Ozawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine III, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama, 641-8509, Japan. u1.ozawa@wakayama-med.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Nucleotidyltransferases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The impact of cGAS/STING tumor expression on PD-1/L1 inhibitor efficacy and the tumor microenvironment remain to be elucidated. METHODS: In a post-hoc analysis of a prospective biomarker study with 106 advanced NSCLC patients treated with PD-1/L1 inhibitors from December 2015 to September 2018, tumor tissue before treatment from 68 patients was analyzed. cGAS and STING expression were measured using immunohistochemical staining and H-scores. Additionally, 40 serum proteins were quantified before and 4-6 weeks after treatment initiation. RESULTS: Median cGAS and STING H-scores were 220 (range, 5-300) and 190 (range, 0-300), respectively. There were no differences in cGAS or STING H-scores between the high (tumor proportion score [TPS] ≥ 50) and low (TPS < 50) PD-L1groups (p = 0.990 and 0.283, respectively). Unexpectedly, patients with high cGAS (H-score ≥ 220) demonstrated significantly shorter progression-free survival (PFS) of PD-1/L1 inhibitors when the PD-L1 TPS was high (median PFS: 143 days vs. not reached; p = 0.028); PFS at 18 months was 7% and 53% in the high and low cGAS groups, respectively while STING expression did not impact PFS. In serum protein analyses, high cGAS H-score was associated with significantly higher TGF-β1 and TGF-β2 before PD-1/L1 inhibition (47.5 vs. 22.3 ng/l, p = 0.023; 2118 vs. 882 pg/ml, p = 0.037); additionally, the cGAS H-score significantly correlated with TGF-β1 (r = 0.451, p = 0.009) and TGF-β2 (r = 0.375, p = 0.031) basal levels. CONCLUSION: cGAS expression, but not STING, predicts poor PD-1/L1 inhibitor efficacy in NSCLC with high PD-L1, potentially due to a TGF-β-mediated immunosuppressive environment (UMIN000024414).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNucleotidyltransferasesImmune Checkpoint InhibitorsB7-H1 AntigenBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overProgrammed Cell Death 1 ReceptorMembrane ProteinsProspective StudiesPrognosisTumor MicroenvironmentCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseSTING Protein

Stichwörter der Autor:innen

Immune checkpoint inhibitorLung cancerPD-L1STINGTGF-bcGAS

Substanzen

NucleotidyltransferasesImmune Checkpoint InhibitorsB7-H1 AntigenBiomarkers, TumorProgrammed Cell Death 1 ReceptorMembrane ProteinscGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseCD274 protein, humanSTING1 protein, human

Autor:innen und Institutionen

  • Internal Medicine III, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama, 641-8509, Japan. u1.ozawa@wakayama-med.ac.jp.
  • Department of Respiratory Medicine, Hamamatsu Medical Center, 328, Tomitsuka, Hamamatsu City, Shizuoka, 432-8580, Japan. u1.ozawa@wakayama-med.ac.jp.
  • Medical Oncology, Hamamatsu Medical Center, Hamamatsu, Japan. u1.ozawa@wakayama-med.ac.jp.
  • Internal Medicine III, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama, 641-8509, Japan.
  • Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.
  • Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Förderung

  • JSPS KAKENHI

Zitieren

APA

Ozawa, Y., Koh, Y., Shibaki, R., Harutani, Y., Akamatsu, H., Hayata, A., Sugimoto, T., Kitamura, Y., Fukuoka, J., Nakanishi, M., & Yamamoto, N. (2024). Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03861-9

Vancouver

Ozawa Y, Koh Y, Shibaki R, Harutani Y, Akamatsu H, Hayata A, et al. Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03861-9

BibTeX
@article{Ozawa2024,
  author = {Ozawa, Yuichi and Koh, Yasuhiro and Shibaki, Ryota and Harutani, Yuhei and Akamatsu, Hiroaki and Hayata, Atsushi and Sugimoto, Takeya and Kitamura, Yuka and Fukuoka, Junya and Nakanishi, Masanori and Yamamoto, Nobuyuki},
  title = {Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03861-9}
}
Kostenlos starten →